Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease
Open accessThe DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
The positron emission tomography (PET) radiotracer Pittsburgh Compound-B (PiB) binds with high affinity to beta-pleated sheet aggregates of the amyloid-beta (Abeta) peptide in vitro. The in vivo retention of PiB in brains of people with Alzheimer's disease shows a regional distribution that is very similar to distribution of Abeta deposits observed post-mortem. However, the basis for regional variations in PiB binding in vivo, and the extent to which it binds to different types of Abeta-containing plaques and tau-containing neurofibrillary tangles (NFT), has not been thoroughly investigated. The present study examined 28 clinically diagnosed and autopsy-confirmed Alzheimer's disease subjects, including one Alzheimer's disease subject who had undergone PiB-PET imaging 10 months prior to death, to evaluate region- and substrate-specific binding of the highly fluorescent PiB derivative 6-CN-PiB. These data were then correlated with region-matched Abeta plaque load and peptide levels, [(3)H]PiB binding in vitro, and in vivo PET retention levels. We found that in Alzheimer's disease brain tissue sections, the preponderance of 6-CN-PiB binding is in plaques immunoreactive to either Abeta42 or Abeta40, and to vascular Abeta deposits. 6-CN-PiB labelling was most robust in compact/cored plaques in the prefrontal and temporal cortices. While diffuse plaques, including those in caudate nucleus and presubiculum, were less prominently labelled, amorphous Abeta plaques in the cerebellum were not detectable with 6-CN-PiB. Only a small subset of NFT were 6-CN-PiB positive; these resembled extracellular 'ghost' NFT. In Alzheimer's disease brain tissue homogenates, there was a direct correlation between [(3)H]PiB binding and insoluble Abeta peptide levels. In the Alzheimer's disease subject who underwent PiB-PET prior to death, in vivo PiB retention levels correlated directly with region-matched post-mortem measures of [(3)H]PiB binding, insoluble Abeta peptide levels, 6-CN-PiB- and Abeta plaque load, but not with measures of NFT. These results demonstrate, in a typical Alzheimer's disease brain, that PiB binding is highly selective for insoluble (fibrillar) Abeta deposits, and not for neurofibrillary pathology. The strong direct correlation of in vivo PiB retention with region-matched quantitative analyses of Abeta plaques in the same subject supports the validity of PiB-PET imaging as a method for in vivo evaluation of Abeta plaque burden.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





![Fig. 6 Correlations of the in vivo PiB DVR values from the 19 VOIs (six of the 25 VOIs had <70% tissue and were not included in the analysis, see Methods section) on the PET scan with post-mortem quantifications of 6-CN-PiB (A) or Aβ (B) plaque load, neurofibrillary load (C) and [3H]PiB binding (D) in the corresponding 19 tissue cubes from the formalin fixed left hemisphere. In vivo PiB-PET retention (DVR) levels correlate directly with regional post-mortem quantitations of 6-CN-PiB (A) and 6E10 (B) plaque loads as well as in vitro PiB binding (D), but not with AT8 neurofibrillary load (C) in formalin-fixed tissue from the left hemisphere. In fresh-frozen tissue from the right hemisphere of the same Alzheimer's disease subject, there is a significant correlation of both in vitro PiB binding (E) and total insoluble Aβ (Aβ1–40 + Aβ1–42) peptide levels (F) with in vivo PiB-PET retention (DVR) levels.](https://figures.cochat.ai/paper-figures/e33db6b5b74a421cb6ab860a36a812a8/post-mortem-correlates-of-in-vivo-pib-pet-amyloid-imaging-in-a-typical-case-of-figure-6.jpg)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“in accordance with the relative resistance of this region to pathology in mouse AD models and AD patients26”
From Transcriptional signature in microglia associated with Aβ plaque phagocytosis (2021) · cites this paper as [26]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent amyloid imaging techniques have proved an association with Alzheimer disease pathology235 and may prove useful for evaluating the independent and combined effects of vascular and Alzheimer disease brain injury on cognitive changes during normal aging in the future.”
The cited source says what the claim attributes to it.
In the citing paper
“Imaging-to-autopsy comparison studies have established that amyloid positron emission tomography (PET) is a valid in vivo surrogate for Aβ deposits (in brain parenchyma/vessel walls) [17–24].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“the [11C]-benzothiazole radiotracer, Pittsburgh Compound B (PIB), as well as other tracers, can bind to fibrillar Aβ plaques, allowing for visualization of brain amyloid in individuals during positron emission tomography (PET) (23-25).”
From Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance (2011) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 3×
“In this case, the final neuropathological diagnosis by CERAD criteria (Mirra et al., 1991) was ‘definite Alzheimer’s disease’, and the Braak stage (Braak and Braak, 1991b) was V/VI.”
BackgroundResultMirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496 · cited 7×
“…Alzheimer’s disease patients have 2- to 3-fold greater PiB retention on PET scans in brain areas known to have high amounts of fibrillar (i.e. Congo red and thioflavin-S labelled) Ab plaques in Alzheimer’s disease, such as frontal cortex and temporal lobe (Klunk et al., 2004; Price et al., 2005).”
BackgroundInfluentialSelf-citationGauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G. G., & Heyman, A. (2002) · Principles and Practice of Geriatric Psychiatry · doi:10.1002/0470846410.ch42(iii · Cited by 2,410
Simplified Reference Tissue Model for PET Receptor Studies
Lammertsma, A. A., & Hume, S. P. (1996) · NeuroImage · doi:10.1006/nimg.1996.0066 · Cited by 2,021 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
MethodIwatsubo, T., Odaka, A., Suzuki, N., Mizusawa, H., Nukina, N., & Ihara, Y. (1994) · Neuron · doi:10.1016/0896-6273(94)90458-8 · Cited by 1,774 · cited 1×
“Ab42-containing plaques and Ab42 peptide levels are much more abundant in Alzheimer’s disease brain (Iwatsubo et al., 1994; Naslund et al., 2000), and therefore likely drive the correlation between PiB and total Ab peptide (Ab42 and Ab40 combined) levels as determined in our ELISA assays.”
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G.-J., Ding, Y.-S., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,514 · cited 1×
“Logan graphical analyses (Logan et al., 1996) were performed for 35–60min (5 points) intervals using input functions derived from cerebellar tissue radioactivity to yield the DVR as the outcome measure (Lammertsma and Hume, 1996).”
Method
Research works printed but not linked: 2
- Braak, 1991, Neuropathological staging of Alzheimer's disease, Acta Neuropath, 82, 239, 10.1007/BF00308809 · DOI · Paper page
- Kim, 1990, Detection and quantification of β-peptide with two monoclonal antibodies, Neurosci Res Commun, 7, 113
Cited by
Items 401–500 of 963
Amyloid and Tau PET Imaging of Alzheimer Disease and Other Neurodegenerative Conditions
Rowley, P. A., Samsonov, A. A., Betthauser, T. J., Pirasteh, A., Johnson, S. C., & Eisenmenger, L. B. (2020) · Seminars in Ultrasound CT and MRI · doi:10.1053/j.sult.2020.08.011 · Cited by 42
Amyloid‐ β PET and CSF in an autopsy‐confirmed cohort
Reimand, J., Boon, B. D. C., Collij, L. E., Teunissen, C. E., Rozemüller, A. J. M., van Berckel, B. N. M., Scheltens, P., Ossenkoppele, R., & Bouwman, F. H. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51195 · Cited by 45
Lizio, R., Percio, C. D., Marzano, N., Soricelli, A., Yener, G., Başar, E., Mundi, C., Rosa, S. D., Triggiani, A. I., Ferri, R., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-143042 · Cited by 44
The neurobiology of Alzheimer disease defined by neuroimaging
Masdeu, J. C., Kreisl, W. C., & Berman, K. F. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283557b36 · Cited by 37
Principal component analysis of PiB distribution in Parkinson and Alzheimer diseases
Campbell, M. C., Markham, J., Flores, H. P., Hartlein, J. M., Goate, A., Cairns, N. J., Videen, T. O., & Perlmutter, J. S. (2013) · Neurology · doi:10.1212/wnl.0b013e31829e6f94 · Cited by 39
Moderate‐ to high‐intensity exercise does not modify cortical β‐amyloid in Alzheimer's disease
Frederiksen, K. S., Madsen, K., Andersen, B. B., Beyer, N., Garde, E., Høgh, P., Waldemar, G., Hasselbalch, S. G., & Law, I. (2019) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.04.006 · Cited by 36
“Amyloid PET is a measure of brain fibrillary Ab [36], whereas CSF Ab may instead reflect soluble species of Ab and, as such, is only an indirect measure of fibrillary Ab [37].”
BackgroundAmyloid-β and τ biomarkers in Parkinson's disease–dementia
Buongiorno, M., Compta, Y., & Martí, M. J. (2011) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2011.06.046 · Cited by 43
“This binding pattern for both radiotracers has been backed by in vivo studies as well [38,39].”
Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease
Hirao, K., Pontone, G. M., & Smith, G. S. (2014) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2014.11.010 · Cited by 40
Frigerio, I., Boon, B. D. C., Lin, C., Graaf, Y. G.-D., Bol, J. G. J. M., Preziosa, P., Twisk, J. W. R., Barkhof, F., Hoozemans, J. J. M., Bouwman, F. H., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab281 · Cited by 41
Pittsburgh compound B and the postmortem diagnosis of alzheimer disease
Niedowicz, D. M., Beckett, T. L., Matveev, S., Weidner, A. M., Baig, I., Kryscio, R. J., Mendiondo, M. S., LeVine, H., Keller, J. N., & Murphy, M. P. (2012) · Annals of Neurology · doi:10.1002/ana.23633 · Cited by 38
McGrath, E. R., Beiser, A., O’Donnell, A., Yang, Q., Ghosh, S., Gonzales, M. M., Himali, J. J., Satizábal, C. L., Johnson, K. A., Tracy, R. P., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215639 · Cited by 40
“The PET acquisition and processing protocols have previously been described [14, 15] and have been validated against tissue A (cid:2) burden at autopsy [16].”
A History of Senile Plaques: From Alzheimer to Amyloid Imaging
Beach, T. G. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac030 · Cited by 41
Amyloid-plaque imaging in early and differential diagnosis of dementia
Drzezga, A. E. (2010) · Annals of Nuclear Medicine · doi:10.1007/s12149-009-0330-9 · Cited by 40
“facto amyloid-plaque depositions in the patients’ brains [ 41 , 42], a true quantitative relation could not yet be established in these trials.”
BackgroundMethodShould We Disclose Amyloid Imaging Results to Cognitively Normal Individuals?
Grill, J. D., Johnson, D. K., & Burns, J. M. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.12.75 · Cited by 36
“Amyloid PET ligands bind to the fibrillar Aβ of neuritic plaques that are the pathological hallmark of AD [6, 7].”
BackgroundSynergistic effects of longitudinal amyloid and vascular changes on lobar microbleeds
Kim, Y. J., Kim, H. J., Park, J., Kim, S., Woo, S., Kwak, K., Lee, J. M., Jung, N., Kim, J. S., Choe, Y. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003220 · Cited by 38
Mi, Z., Abrahamson, E. E., Ryu, A. Y., Fish, K. N., Sweet, R. A., Mufson, E. J., & Ikonomović, M. D. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.022 · Cited by 39
“This could partially explain the correlation we observed between lower spinophilin-ir dendritic spines and greater Aβ plaque load visualized by 6-CN-PiB, which labels mature neuritic plaques more prominently than diffuse plaques (Ikonomovic et al., 2008) (see Fig.”
BackgroundMethodSelf-citationGiulietti, G., Torso, M., Serra, L., Spanò, B., Marra, C., Caltagirone, C., Cercignani, M., Bozzali, M., & (ADNI), T. A. D. N. I. (2018) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.25947 · Cited by 39
The Effects of YAP and Its Related Mechanisms in Central Nervous System Diseases
Jin, J., Zhao, X., Fu, H., & Gao, Y. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00595 · Cited by 41
Retinal Amyloid Imaging for Screening Alzheimer’s Disease
Tadokoro, K., Yamashita, T., Kimura, S., Nomura, E., Ohta, Y., Omote, Y., Takemoto, M., Hishikawa, N., Morihara, R., Morizane, Y., et al. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-210327 · Cited by 37
“Positive amyloid positron emission tomography (PET) [3] or a decrease of amyloid-(cid:2) 42 content in cerebrospinal fluids (CSF) [4] indicates AD pathology in living patients, but these are too expensive or excessively invasive for routine use.”
Tago, T., Furumoto, S., Okamura, N., Harada, R., Adachi, H., Ishikawa, Y., Yanai, K., Iwata, R., & Kudo, Y. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0879-8 · Cited by 37
Sojkova, J., & M. Resnick, S. (2011) · Current Alzheimer Research · doi:10.2174/156720511795745375 · Cited by 36
The prognostic value of amyloid imaging
Gelosa, G., & Brooks, D. J. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2108-x · Cited by 36
“The cardinal features of AD pathology are amyloid plaques, neurofibrillary tangles (NFTs), cortical and hippocampal cell loss, activated microglia, and reductions in cortical acetylcholine levels [8].”
BackgroundInfluentialComparison of dual-biomarker PIB-PET and dual-tracer PET in AD diagnosis
Fu, L., Liu, L., Zhang, J., Xu, B., Fan, Y., & Tian, J. (2014) · European Radiology · doi:10.1007/s00330-014-3311-x · Cited by 39
Rabinovici, G. D., Karlawish, J., Knopman, D., Snyder, H. M., Sperling, R., & Carrillo, M. C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.002 · Cited by 36
Impact of Amyloid PET Imaging in the Memory Clinic: A Systematic Review and Meta-Analysis
Shea, Y. F., Barker, W., Greig-Gusto, M. T., Loewenstein, D., Duara, R., & DeKosky, S. T. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180239 · Cited by 38
Self-citationDilated Convolutional Neural Networks for Sequential Manifold-Valued Data
Chakraborty, R., Zhen, X., Vogt, N., Bendlin, B. B., & Singh, V. (2019) · IEEE/CVF International Conference on Computer Vision (ICCV) · doi:10.1109/iccv.2019.01072 · Cited by 44
“Positron emission tomography (PET) imaging with Pittsburgh compound B (PiB), which identifies amyloid deposition, can be used as an indicator of AD pathology [28].”
BackgroundRole of Cofilin in Alzheimer’s Disease
Wang, Q., Yuan, W., Yang, X., Wang, Y., Li, Y., & Qiao, H. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.584898 · Cited by 35
Diagnosis of neurodegenerative dementia: where do we stand, now?
Sancesario, G. M., & Bernardini, S. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.08.04 · Cited by 36
“Thereafter a positron emission tomography (PET) method was developed for in vivo evaluation of Aβ plaque burden in vivo (2).”
BackgroundMethodPreclinical studies of potential amyloid binding PET/SPECT ligands in Alzheimer's disease
Svedberg, M. M., Rahman, O., & Hall, H. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2011.10.007 · Cited by 35
“95 nM [74].”
Li, J., Zhang, Q., Chen, F., Yan, J., Kim, S., Wang, L., Feng, W., Saykin, A. J., Liang, H., & Shen, L. (2015) · BioMed Research International · doi:10.1155/2015/647389 · Cited by 35
Zhang, X., Kuang, Q., Xu, J., Lin, Q., Chi, H., & Yu, D. (2024) · Biomolecules · doi:10.3390/biom14050538 · Cited by 40
“Initially, in the assessment of clinical treatments, PiB-PET imaging may not be as effective at identifying soluble amyloid or diffuse amyloid plaques compared to animal models [50].”
BackgroundAlzheimer’s Disease: From Molecular Mechanisms to Promising Therapeutic Strategies
Ivanova, A. V., Kutuzova, A. D., Kuzmichev, I. A., & Abakumov, M. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26199444 · Cited by 35
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease
Någren, K., Halldin, C., & Rinne, J. O. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1301-z · Cited by 37
“Increased [(11)C]PIB uptake detected by PET imaging correlated well with the amount of beta-amyloid deposits in the brain seen either at postmortem [129] or in-vivo biopsy study [130].”
Ricci, M., Cimini, A., Chiaravalloti, A., Filippi, L., & Schillaci, O. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207481 · Cited by 39
Šmid, L. M., Kepe, V., Vinters, H. V., Bresjanac, M., Toyokuni, T., Satyamurthy, N., Wong, K. P., Huang, S., Silverman, D. H. S., Miller, K. J., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-122434 · Cited by 36
Degerman Gunnarsson, M., Lindau, M., Wall, A., Blennow, K., Darreh-Shori, T., Basu, S., Nordberg, A., Larsson, A., Lannfelt, L., Basun, H., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000281832 · Cited by 33
“Further, postmortem correlates of in vivoPET PIB amyloid imaging in AD show a strong association with Aβ plaque burden [”
BackgroundAmyloid Imaging in Early Detection of Alzheimer’s Disease
Nordberg, A. K. (2010) · Neurodegenerative Diseases · doi:10.1159/000289223 · Cited by 35
“It is also important to verify amyloid PET imaging in vivo with amyloid measurement at autopsy. A significant correlation has been reported between in vivo PIB brain retention and Aβ levels and 3 H-PIB binding in autopsy and biopsy tissue [”
BackgroundAmyloid Imaging in Alzheimer’s Disease and Other Dementias
Fodero‐Tavoletti, M. T., Cappai, R., McLean, C., Pike, K. E., Adlard, P. A., Cowie, T., Connor, A. R., Masters, C. L., Rowe, C. C., & Villemagne, V. L. (2009) · Brain Imaging and Behavior · doi:10.1007/s11682-009-9067-2 · Cited by 34
“(Klunk et al. 2003b; Fodero-Tavoletti et al. 2007; Lockhart et al. 2007; Ikonomovic et al. 2008)”
BackgroundMethodInfluentialASAF: altered spontaneous activity fingerprinting in Alzheimer’s disease based on multisite fMRI
Li, J., Jin, D., Li, A., Liu, B., Song, C., Wang, P., Wang, D., Xu, K., Yang, H., Yao, H., et al. (2019) · 中国科学通报:英文版 · doi:10.1016/j.scib.2019.04.034 · Cited by 36
Multimodal Imaging of Alzheimer Pathophysiology in the Brain′s Default Mode Network
Shin, J., Kepe, V., Small, G. W., Phelps, M. E., & Barrio, J. R. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/687945 · Cited by 31
“PET imaging studies with [C11]PIB, which has been suggested to bind to amyloid plaques only [40, 41], show a single pattern of [C-11]PIB binding in the prefrontal, lateral parietal, posterior cingulate, lateral temporal cortices and precuneus [40] at all levels of cognitive impairment, including AD, a subset of MCI su…”
BackgroundBouter, C., Vogelgsang, J. S., & Wiltfang, J. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2019.02.005 · Cited by 35
Regional amyloid correlates of cognitive performance in ageing and mild cognitive impairment
Stevens, D. A., Workman, C. I., Kuwabara, H., Butters, M. A., Savonenko, A. V., Nassery, N., Gould, N. F., Kraut, M. A., Joo, J. H., Kilgore, J. J., et al. (2022) · Brain Communications · doi:10.1093/braincomms/fcac016 · Cited by 32
Morrison, M. S., Aparicio, H. J., Blennow, K., Zetterberg, H., Ashton, N. J., Karikari, T. K., Tripodis, Y., Martin, B. M., Palmisano, J. N., Sugarman, M. A., et al. (2022) · Brain · doi:10.1093/brain/awac175 · Cited by 36
Biomarkers in Alzheimer’s Disease
Riverol, M., & López, O. L. (2011) · Frontiers in Neurology · doi:10.3389/fneur.2011.00046 · Cited by 37
Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease
Pivtoraiko, V. N., Abrahamson, E. E., Leurgans, S. E., DeKosky, S. T., Mufson, E. J., & Ikonomović, M. D. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.06.021 · Cited by 34
“Aβ1-40 and Aβ1-42 concentrations were analyzed in triplicates, using chemiluminescent-based ELISA (Invitrogen, Camarillo, CA, USA) (Ikonomovic et al., 2008).”
MethodSelf-citationBlautzik, J., Initiative, A. D. N., Kotz, S., Brendel, M., Sauerbeck, J., Vettermann, F. J., Winter, Y., Bartenstein, P., Ishii, K., & Rominger, A. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170064 · Cited by 34
“The neurodegenerative process underlying AD 43 is characterized by intracerebral accumulation of 44 amyloid- (A ) plaques and neurofibrillary tangles, 45 which together represent the core histopathological 46 hallmarks of the disease [12].”
Progress and challenges in the diagnosis of dementia: a critical review
Paraskevaidi, M., Martin-Hirsch, P. L., & Martin, F. L. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00007 · Cited by 31
Current neuroimaging techniques in Alzheimer's disease and applications in animal models.
Zhang, L., Chang, R. C., Chu, L., & Mak, H. K. (2012) · Europe PMC (PubMed Central) · Cited by 35
Koran, M. E. I., Hohman, T. J., & Thornton‐Wells, T. A. (2013) · Human Genetics · doi:10.1007/s00439-013-1354-8 · Cited by 35
“…living patients, have been correlated with disease onset and progression, have been validated post-mortem, and more recently have been included as biomarkers for classifying patients with AD in research studies (Ikonomovic et al. 2008; Clark et al. 2011; Albert et al. 2011; Sperling et al. 2011).”
Reimand, J., de Wilde, A., Teunissen, C. E., Zwan, M. D., Windhorst, A. D., Boellaard, R., Barkhof, F., van der Flier, W. M., Scheltens, P., van Berckel, B. N. M., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0561-5 · Cited by 34
Neuropathologic correlates of amyloid and dopamine transporter imaging in Lewy body disease
Shirvan, J. C., Clement, N. F., Ye, R., Katz, S. R., Schultz, A. P., Johnson, K. A., Gómez‐Isla, T., Frosch, M. P., Growdon, J. H., & Gomperts, S. N. (2019) · Neurology · doi:10.1212/wnl.0000000000007855 · Cited by 33
Amyloid PET Ligands for Dementia
Villemagne, V. L., & Rowe, C. C. (2010) · PET Clinics · doi:10.1016/j.cpet.2009.12.008 · Cited by 32
Tuzzi, E., Balla, D. Z., Loureiro, J. R., Neumann, M., Laske, C., Pohmann, R., Preische, O., Scheffler, K., & Hagberg, G. E. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-190424 · Cited by 35
“Furthermore, there is evidence that the 11 C agent also binds to diffuse plaques in the parenchyma and cerebral A (cid:2) angiopathy at vessels [13, 16, 19, 20] thus reducing the specificity of 11 C-PiB PET for in vivo diagnosis of AD.”
Regional analysis of striatal and cortical amyloid deposition in patients with A lzheimer's disease
Ishibashi, K., Ishiwata, K., Toyohara, J., Murayama, S., & Ishii, K. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12633 · Cited by 32
Initiative, A. D. N., Blautzik, J., Brendel, M., Sauerbeck, J., Kotz, S., Scheiwein, F., Bartenstein, P., Seibyl, J. P., & Rominger, A. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3666-8 · Cited by 30
“brain together representing the core histopathological hallmarks of AD [1].”
BackgroundVillemagne, V. L., & Rowe, C. C. (2011) · International Psychogeriatrics · doi:10.1017/s1041610211000895 · Cited by 30
Omar, M. A., El‐Shiekh, R. A., Dawood, D. H., Temirak, A., & Srour, A. M. (2023) · Future Medicinal Chemistry · doi:10.4155/fmc-2023-0238 · Cited by 33
Brain effective connectivity modeling for alzheimer's disease by sparse gaussian bayesian network
Huang, S., Li, J., Ye, J., Fleisher, A., Chen, K., Wu, T., & Reiman, E. M. (2011) · ACM SIGKDD Conference on Knowledge Discovery and Data Mining (KDD) · doi:10.1145/2020408.2020562 · Cited by 34
“A possible interpretation is that these are neocortical regions associated with amyloid deposition and early FDG hypometabolism in AD [34-37, 41-42].”
BackgroundInvestigation of 11C-PiB equivocal PET findings
Hosokawa, C., Ishii, K., Hyodo, T., Sakaguchi, K., Usami, K., Shimamoto, K., Yamazoe, Y., Hosono, M., Hanada, K., Ueda, M., et al. (2014) · Annals of Nuclear Medicine · doi:10.1007/s12149-014-0924-8 · Cited by 29
Molecular imaging in the diagnosis of Alzheimer's disease and related disorders
Koric, L., Guedj, É., Habert, M., Semah, F., Branger, P., Payoux, P., & Jeune, F. L. (2016) · Revue Neurologique · doi:10.1016/j.neurol.2016.10.009 · Cited by 31
Imaging Biomarkers in Alzheimer’s Disease: A Practical Guide for Clinicians
Sheikh‐Bahaei, N., Sajjadi, S. A., Manavaki, R., & Gillard, J. H. (2017) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-170013 · Cited by 32
Mathematical analysis for stochastic model of Alzheimer’s disease
Zhang, Y., & Wang, W. (2020) · Communications in Nonlinear Science and Numerical Simulation · doi:10.1016/j.cnsns.2020.105347 · Cited by 37
Wang, Z.-T., Shen, X.-N., Ma, Y.-H., Ou, Y.-N., Dong, P. Q., Tan, P. L., & Yu, P. J.-T. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.10.078 · Cited by 28
“Previous studies have established that positron emission tomography (PET)-based molecular (e.g., A β and tau) imaging is a valid in vivo surrogate for AD pathology (Clark et al., 2012; Fleisher et al., 2011; Ikonomovic et al., 2008; Jack et al., 2018; Josephs et al., 2016; Seo et al., 2017).”
de Souza, L. C., Lehéricy, S., Dubois, B., Stella, F., & Sarazin, M. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328357b9ab · Cited by 30
Boerwinkle, A. H., Wisch, J. K., Chen, C. D., Gordon, B. A., Butt, O. H., Schindler, S. E., Sutphen, C., Flores, S., Dincer, A., Benzinger, T. L. S., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012123 · Cited by 28
“Our results are in agreement with hypothesized changes in CSF Aβ42 occurring prior to the formation of mature plaques that are measured by PET amyloid tracers.(35,36) Prior work that has classified individuals as amyloid-positive or amyloid-negative on the basis of either CSF or PET has identified more individuals as…”
Result11C-PiB PET can underestimate brain amyloid-β burden when cotton wool plaques are numerous
Abrahamson, E. E., Kofler, J., Becker, C. R., Price, J. C., Newell, K. L., Ghetti, B. F., Murrell, J. R., McLean, C., López, O. L., Mathis, C. A., et al. (2021) · Brain · doi:10.1093/brain/awab434 · Cited by 33
Self-citationPiB Fails to Map Amyloid Deposits in Cerebral Cortex of Aged Dogs with Canine Cognitive Dysfunction
Fast, R., Rodell, A. B., GJEDDE, A. H., Mouridsen, K., Alstrup, A. K. O., Bjarkam, C. R., West, M. J., Berendt, M., & Møller, A. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00099 · Cited by 28
“Compared to cognitively intact control subjects, AD patients exhibit greater [11C]PiB retention in areas known to contain substantial accumulations of Aβ deposits, including the frontal and parietal cortices, whereas brain areas relatively unaffected by Aβ pathology, such as the cerebellum, show little or no [11C]PiB…”
BackgroundResultInfluentialCytokines and Cytokine Receptors Involved in the Pathogenesis of Alzheimers Disease
Nagae, T., Araki, K., Shimoda, Y., Sue, L. I., Beach, T. G., & Konishi, Y. (2016) · Journal of Clinical & Cellular Immunology · doi:10.4172/2155-9899.1000441 · Cited by 30
“In the cerebellum of AD patients used in our study, only sparse diffuse and cored plaques were observed (Table S1); that is, no typical plaques associated neuritic alterations, NFTs, or glial reactions were found, in agreement with previous findings [82-85].”
ResultCurrent Role for Biomarkers in Clinical Diagnosis of Alzheimer Disease and Frontotemporal Dementia
Sheikh‐Bahaei, N., Sajjadi, S. A., & Pierce, A. L. (2017) · Current Treatment Options in Neurology · doi:10.1007/s11940-017-0484-z · Cited by 29
Furr, J. W., Morales‐Scheihing, D., Manwani, B., Lee, J., & McCullough, L. D. (2019) · NeuroMolecular Medicine · doi:10.1007/s12017-019-08568-0 · Cited by 29
Alavi, A. A., Barrio, J. R., Werner, T. J., Khosravi, M., Newberg, A. B., & Høilund‐Carlsen, P. F. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04564-5 · Cited by 30
An Expanded Role for Neuroimaging in the Evaluation of Memory Impairment
Desikan, R. S., Rafii, M. S., Brewer, J. B., & Hess, C. P. (2013) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3644 · Cited by 29
“in autopsy-confirmed AD but does not associate with NFTs, Lewy bodies, or other protein aggregates.(32,33) In humans, the overall pattern of increased PIB retention mirrors the distribution of”
BackgroundAlmdahl, I. S., Lauridsen, C., Selnes, P., Kalheim, L. F., Coello, C. S., Gajdzik, B., Møller, I., Wettergreen, M., Grambaitė, R., Bjørnerud, A., et al. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00009 · Cited by 28
“Uptake of amyloid-binding PET tracers, like 18F-Flutemetamol (18FFLUT), correlates inversely with CSF Aβ42 levels (Fagan et al., 2006; Li et al., 2015), and positively with Aβ plaque burden observed post-mortem (Ikonomovic et al., 2008).”
Fissers, J., Waldron, A., Vijlder, T. D., Broeck, B. V., Pemberton, D. J., Mercken, M. H., der Veken, P. V., Joossens, J., Augustyns, K., Dedeurwaerdere, S., et al. (2016) · Molecular Imaging and Biology · doi:10.1007/s11307-016-0935-z · Cited by 28
Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer’s Disease Progression
Chen, X., Zhou, Y., Wang, R., Cao, H., Reid, S., Gao, R., Han, D., & Initiative, A. D. N. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154406 · Cited by 27
“The correlation between the measurement of PET amyloid imaging and histological evidence of Aβ deposition were ascertained by several studies [8, 9].”
BackgroundThe presubiculum links incipient amyloid and tau pathology to memory function in older persons
Jacobs, H. I. L., Augustinack, J. C., Schultz, A. P., Hanseeuw, B. J., Locascio, J. J., Amariglio, R. E., Papp, K. V., Rentz, D. M., Sperling, R. A., & Johnson, K. A. (2020) · Neurology · doi:10.1212/wnl.0000000000009362 · Cited by 28
Stonebarger, G. A., Urbanski, H. F., Woltjer, R. L., Vaughan, K. L., Ingram, D., Schultz, P., Calderazzo, S. M., Siedeman, J., Mattison, J., Rosene, D. L., et al. (2020) · GeroScience · doi:10.1007/s11357-020-00259-0 · Cited by 27
Wiatrak, B., & Balon, K. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02204-w · Cited by 29
Molecular imaging of beta-amyloid deposition in late-life depression
Smith, G. S., Kuwabara, H., Nandi, A., Gould, N. F., Nassery, N., Savonenko, A. V., Joo, J. H., Kraut, M. A., Brašić, J. R., Holt, D. P., et al. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.002 · Cited by 28
Chen, C. D., Joseph‐Mathurin, N., Sinha, N., Zhou, A., Li, Y., Friedrichsen, K. A., McCullough, A. A., Franklin, E. E., Hornbeck, R. C., Gordon, B. A., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02342-y · Cited by 28
“Of note among these is a study by Ikonomovic and colleagues, which compared PiB PET distribution volume ratios (DVRs) and quantitative—but not stereologic—assessment of 6-CN-PiB stained and 6E10 immunostained amyloid-β plaques in a single LOAD individual across 19 regions of interest, including the cortical ribbon and…”
BackgroundSelf-citationPost-Mortem MRI and Histopathology in Neurologic Disease: A Translational Approach
Jonkman, L. E., Kenkhuis, B., Geurts, J. J. G., & van de Berg, W. D. J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00342-3 · Cited by 30
Wang, M. J., Yi, S., Han, J.-Y., Park, Y. H., Jang, J., Chun, I. K., Giau, V. V., Bagyinszky, E., Lim, K., Kang, S. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160143 · Cited by 27
“AmyloidPETisrelated toasfibrillarA [40], whereas CSF A 42 is a marker of soluble A 42 [41].”
Cerebral Amyloid Angiopathy Pathology and Its Association With Amyloid-β PET Signal
McCarter, S. J., Lesnick, T. G., Lowe, V. J., Mielke, M. M., Constantopoulos, E., Rabinstein, A. A., Przybelski, S. A., Botha, H., Jones, D. T., Ramanan, V. K., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012770 · Cited by 27
“On the other hand, pathologic studies of D-CAA show diffuse and neuritic plaques, especially in older patients, and PiB has been shown to bind to both neuritic and diffuse plaques, albeit to a lesser degree to the latter.(22,23) One prior case of a patient with dementia with Lewy bodies who had positive PiBPET imaging…”
Hosokawa, C., Ishii, K., Kimura, Y., Hyodo, T., Hosono, M., Sakaguchi, K., Usami, K., Shimamoto, K., Yamazoe, Y., & Murakami, T. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.156414 · Cited by 29
Preventive immunization of aged and juvenile non-human primates to beta-amyloid
Kofler, J., Lopresti, B. J., Janssen, C., Trichel, A. M., Masliah, E., Finn, O. J., Salter, R. D., MURDOCH, G. H., Mathis, C. A., & Wiley, C. A. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-84 · Cited by 27
“No significant [(11)C]PiB-PET signal was detected in any of the analyzed brain regions, indicating a relatively low level of fibrillar Aβ in these brains [36].”
BackgroundSelf-citationMeasuring Target Effect of Proposed Disease-Modifying Therapies in Alzheimer's Disease
Bateman, R. J., & Klunk, W. E. (2008) · Neurotherapeutics · doi:10.1016/j.nurt.2008.05.009 · Cited by 26
“Careful correlation of in vivo PiB retention with histology in autopsy samples from an AD patient who had been imaged with PiB prior to death showed that PiB binds to fibrillar A (whether in diffuse-appearing or compact plaques or cerebrovascular amyloid), but not to tau in tangles.(50) PiB does not appear to detect L…”
BackgroundInfluentialSelf-citationDown syndrome: age-dependence of PiB binding in postmortem frontal cortex across the lifespan
LeVine, H., Spielmann, H. P., Matveev, S., Cauvi, F. M., Murphy, M. P., Beckett, T. L., McCarty, K. L., Lott, I. T., Doran, E. W., Schmitt, F. A., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.03.005 · Cited by 29
“Sections were first mounted on slides and allowed to dry prior to incubation in 100 nM CN-PiB for 1 hour at room temperature using a similar protocol as published previously (Ikonomovic et al., 2008) but at a lower concentration closer to the CN-PiB Kd to focus on high affinity imaging ligand-relevant binding.”
BackgroundMethodInfluentialPadovani, A., Benussi, A., Cotelli, M. S., Ferrari, C., Cantoni, V., Dell’Era, V., Turrone, R., Paghera, B., & Borroni, B. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0555-3 · Cited by 27
Amyloid Beta Peptides Differentially Affect Hippocampal Theta Rhythms In Vitro
Gutiérrez-Lerma, A. I., Ordaz, B., & Peña‐Ortega, F. (2013) · International Journal of Peptides · doi:10.1155/2013/328140 · Cited by 30
Matveev, S. V., Spielmann, H. P., Metts, B. M., Chen, J., Onono, F., Zhu, H., Scheff, S. W., Walker, L. C., & LeVine, H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12815 · Cited by 24
“Formic acid treatment of tissue sections also has been shown to abolish PIB binding (Ikonomovic et al. 2008).”
BackgroundAnti-amyloid: An antibody to cure Alzheimer’s or an attitude
Osborne, O., Naranjo, O., Heckmann, B. L., Dykxhoorn, D. M., & Toborek, M. J. (2023) · iScience · doi:10.1016/j.isci.2023.107461 · Cited by 26
“Despite the allegations, there is still compelling evidence in postmortem brain tissue and imaging analyses that amyloid is a major hallmark of the disease.(8) Has our desire to find a cure placed too much emphasis on amyloid at the expense of other putative targets? We would argue that amyloid is a critical determina…”
BackgroundCerebrospinal fluid biomarkers of Alzheimer’s disease in cognitively healthy elderly
Glodzik, L. (2013) · Frontiers in bioscience · doi:10.2741/4170 · Cited by 29
Molecular Imaging of Alzheimer Disease Pathology
Kantarci, K. (2014) · American Journal of Neuroradiology · doi:10.3174/ajnr.a3847 · Cited by 23
“One of the key applications of A PET imaging in clinical practice is in the differential diagnosis of AD.”
BackgroundInfluentialBlood-brain transfer of Pittsburgh compound B in humans
GJEDDE, A. H., Aanerud, J., Brændgaard, H., & Rodell, A. B. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00070 · Cited by 25
“…[11C]PiB retention in areas known to have high Aβ deposits such as the frontal and parietal cortices, whereas brain areas relatively unaffected by Aβ pathology, such as the cerebellum, show equivalently modest [11C]PiB retention (Klunk et al., 2004; Price et al., 2005; Ikonomovic et al., 2008).”
BackgroundInfluentialLeinonen, V., Rinne, J. O., Wong, D. F., Wolk, D. A., Trojanowski, J. Q., Sherwin, P. F., Smith, A. P. L., Heurling, K., Su, M., & Grachev, I. D. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-46 · Cited by 24
Iikuni, S., Ono, M., Watanabe, H., Matsumura, K., Yoshimura, M., Harada, N., Kimura, H., Nakayama, M., & Saji, H. (2014) · Molecular Pharmaceutics · doi:10.1021/mp400499y · Cited by 24
Pandya, S., Initiative, A. D. N., Kuceyeski, A. F., & Raj, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160090 · Cited by 24
Half-curcumin analogues as PET imaging probes for amyloid beta species
Yang, J., Cheng, R., Fu, H., Yang, J., Kumar, M., Lu, J., Xu, Y., Liang, S. H., Cui, M., & Ran, C. (2019) · Chemical Communications · doi:10.1039/c8cc10166c · Cited by 25
Badachhape, A., Working, P. K., Srivastava, M., Bhandari, P., Stupin, I. V., Devkota, L., Tanifum, E. A., Annapragada, A., & Ghaghada, K. B. (2020) · Scientific Reports · doi:10.1038/s41598-020-73233-7 · Cited by 26
Functional Neuroimaging in Geriatric Depression
Gunning, F. M., & Smith, G. S. (2011) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.02.010 · Cited by 25
“40,41 The one study of geriatric depressed patients observed decreased 5-HT1A binding in the dorsal raphe as well as in the middle temporal cortex and hippocampus.42 A similar selective reduction in 5-HT1A binding in temporal cortex has also been observed in patients with AD,43 which might suggest that decreased serot…”
Metadata
- Authors
- Ikonomovic, M. D., Klunk, W. E., Abrahamson, E. E., Mathis, C. A., Price, J. C., Tsopelas, N. D., Lopresti, B. J., Ziolko, S., Bi, W., Paljug, W. R., Debnath, M. L., Hope, C. E., Isanski, B. A., Hamilton, R. L., & DeKosky, S. T.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- DeKosky, Steven T.
- ORCID
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-03-12
- Volume
- 131
- Issue
- 6
- Pages
- 1630-1645
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- PMC
- PMC2408940
- OpenAlex
- W2156981442
- Cited by
- 933
- References
- 66
- Citations by year
- 2026: 16 · 2025: 24 · 2024: 29 · 2023: 25 · 2022: 33 · 2021: 42 · 2020: 44 · 2019: 56 · 2018: 51 · 2017: 46 · 2016: 58 · 2015: 57 · 2014: 82 · 2013: 81 · 2012: 79
- FWCI
- 47.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- Locations
- Brain (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, public-domain)
- Funders
- U.S. Department of Energy (FG02-03ER63590, DE-FD02-03 ER63590, ER63590, DE-FD02-03)
- Alzheimer's Association (AG14449, TLL-01-3381)
- University of Pittsburgh (AG05133)
- National Institute for Health and Care Research
- National Institutes of Health (AG05133, AG025204, AG14449, AG025516)
- National Institute on Aging (AG 05-133, R01AG018402, P01AG025204, RF1AG025516, P50AG005133, P01AG014449, R01AG020226, AG025516, K02AG001039, P01 AG14449, P50-AG-05133, R37AG025516, R01AG025516)
- National Institute of Mental Health (R01MH070729, K01MH001976)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- Alzheimer's disease, amyloid plaques, Pittsburgh compound B, neurofibrillary tangles, tau protein, postmortem brain, amyloid-beta 42, Aβ40, vascular amyloid deposits, prefrontal cortex, temporal cortex, cerebellum
- MeSH terms
- Alzheimer Disease, Aniline Compounds, Autopsy, Brain, Carbon Radioisotopes, Enzyme-Linked Immunosorbent Assay, Female, Humans, Image Interpretation, Computer-Assisted, Immunohistochemistry, Magnetic Resonance Imaging, Middle Aged, Thiazoles, Reproducibility of Results, Amyloid beta-Peptides, Neurofibrillary Tangles, tau Proteins, Positron-Emission Tomography, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.